Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Q2 Breathes A Little Life Into Medtech IPO Scene

Executive Summary

After a lackluster first quarter, the medtech IPO scene is gradually livening up with several companies their shares successfully floated on the public markets for the first time in the second quarter. But activity levels are still a far cry from the bonanza of 2015.

You may also be interested in...

Oncimmune Hits IPO Target

Early cancer detection specialist Oncimmune has joined AIM, the London Stock Exchange’s international market for emerging companies, after successfully completing its initial public offering and raising £11m ($15.7m) in gross proceeds. The company’s market capitalization on admission to AIM is around £66.3m; it is trading under the symbol “ONC.L”.

Medtech IPO Environment Cools With Sluggish Q1

If the first quarter’s IPO activity levels are anything to go by, it looks like medtech companies may be facing a cooler public fundraising climate in 2016.

IPO ROUND-UP: Public appetite for medtech stocks on the up

With June proving to be a bumper month for completed IPOs, the first half of 2015 looks well on its way to outperform 2014 when it comes to stock float successes.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts